Trofosfamide in patients with pancreatic cancer

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2485-2487

  Schmidt Sandte, Wibke ^a   Dageförde, Jürgen ^b   Klapdor, Rainer ^c   Wagner, Thomas ^a   Wiedemann, Günther J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Wilhelm Augusta Krankenhaus des DRK   (Germany)

^c Jerusalem Hospital   (Germany)

Author keywords

Pancreatic cancer; Trofosfamide

Indexed keywords

PRODRUG; TROFOSFAMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0345363045     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Loehrer PJ, Williams SD, Einhorn LH, Ansari R: Ifosfamide: an active drug in treatment of adenocarcinoma of the pancreas. J Clin Oncol 3: 367-372, 1985.
2. Fernandez E, La Vecchia C, Porta M, Negri E, Lucchini F, Levi F: Trends in pancreatic cancer mortality in Europe. Int J Cancer 57: 786-792, 1994.
3. Niederhuber JE, Brennan MF, Menck HR: The national cancer data base report on pancreatic cancer. Cancer 76: 1671-1677.
4. American Cancer Society. Cancer facts and figures-1995. Atlanta: American Cancer Society, 1990.
5. Levin RL, Connely RR, DeVesa SS: Demographic characteristics of cancer of the pancreas. Mortality, incidence, and survival. Cancer 47: 1456-1468, 1981.
6. Mohiuddin M, Regine WF, Stevens J, Rosato F, Barbot D, Biermann W, Cantor R: Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 13: 2764-2768, 1995.
7. Lionetto R, Pugliese V, Bruzzi P, Rosso R: No standard treatment for advanced pancreatic cancer. Eur J Cancer 31A(6): 882-827, 1995.
8. Warshaw AL, Fernandez del Castillo C: Pancreatic carcinoma. N Engl J Med 326(7): 455-465, 1992.
9. Britan JD, Desser RR, Kozloff MF: Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-FU, adriamycin and mitomycin (FAM). Cancer Treat Rep 63: 2049 2053, 1997.
10. Wiggans RG, Woolley PV, MacDonald JS, Smythe T, Ueno W, Schein PS: Phase II trial of streptozotocin, mitomycin C, and 5-FU (SMF) in the treatment of advanced pancreatic cancer. Cancer 41 (2): 387-391, 1987.
11. Bukowski RM, Fleming TR, MacDonald JS, Oishi N, Taylor SA, Baker LH: Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. Cancer 71(2): 322-325, 1993.
12. Cerny T, Martinelli G, Goldhirsch A, Terrier F, Joss R, Fey MF, Brunner KW, Kupfer A: Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 117 Suppl 4: S135-138, 1991.
13. Salminen E, Nikkanen V, Lindholm L: Palliative chemotherapy in Non-Hodgkin_s lymphoma. Oncology 54: 108-111, 1997.
14. Klapdor R, Lehmann U, Bahlo M, Greten H, Ackeren H, Dallek M, Schreiber WH: CA 19-9 a new tumor marker for follow up of exocrine pancreatic cancer. J Cancer Res Clin Oncol 107: 51-55, 1984.
15. Gad El Mawla N: Ifosfamide in advanced pancreatic cancer. Cancer Chemother Pharmacol 18: S55, 1986.